Inactivation of enveloped viruses and killing of cells by fatty acids and monoglycerides

This article is for informational purposes only and is not medical advice. Full disclaimer →

In one sentence: In laboratory testing, stored human milk develops antiviral activity that fresh milk lacks, driven by milk lipases releasing medium-chain free fatty acids. The authors explicitly flagged whether this translates to infant protection as unresolved.

Thormar H, Isaacs CE, et al. · Antimicrobial agents and chemotherapy (1987)

PubMed 3032090 · DOI · PMC full text

Why this paper matters

The paper establishes the mechanistic basis for an observation that had puzzled lactation researchers: why stored human milk acquires antimicrobial activity that fresh milk lacks. Systematic testing identifies milk lipases as the trigger, and medium-chain monoglycerides (including monolaurin) as up to 10× more potent than the corresponding free fatty acids. Crucially, the authors report that these same antiviral fatty acids also lyse mammalian cell membranes at the concentrations tested, and they explicitly flag as unresolved whether protective concentrations are reached in the infant stomach and intestines without damaging tissue. The envelope-disruption mechanism established here is what later GML and medium-chain monoglyceride research builds on, but the 1987 paper itself does not demonstrate in-vivo protective effect.

Background

For decades, researchers knew that human breast milk contained protective factors for infants, primarily immunoglobulins and immune cells. However, a less obvious antimicrobial system lurked in the fat fraction of milk. In the mid-1980s, Halldor Thormar and colleagues investigated why stored human milk—but not fresh milk—could destroy enveloped viruses. Their 1987 paper in Antimicrobial Agents and Chemotherapy systematically tested individual fatty acids and their monoglycerides against multiple virus types, establishing the mechanistic basis for lipid-mediated antiviral activity.

Nearly four decades after Thormar's foundational in-vitro work, monolaurin and related medium-chain fatty acid derivatives are experiencing a research renaissance. A 2025 prospective cohort study of over 1,000 Italian healthcare workers linked higher serum monolaurin levels to reduced COVID-19 risk. Meanwhile, the livestock industry is adopting medium-chain monoglycerides (MCMGs) as GRAS-approved feed additives to combat PEDV, PRRSV, and other enveloped viruses, driven by regulatory bans on prophylactic antibiotics such as the Veterinary Feed Directive in the US.

The Discovery: Breast Milk's Hidden Timer

Fresh breast milk can't kill viruses—but leave it in the fridge and it arms itself.

Fresh human milk has zero antiviral activity, but after storage at 4°C or 23°C for a few days, it becomes potently antiviral due to lipase-driven release of free fatty acids.^{[1, 2]} Thormar et al. showed that the antiviral transformation requires active milk lipases—the enzymes that cleave triglycerides into free fatty acids and monoglycerides. When lipase activity was blocked, no antiviral effect appeared. The timeline of activation correlated precisely with the accumulation of free fatty acids in the milk fat fraction, proving the lipids themselves were the active agents, not immune cells or antibodies.

Stored antiviral human milk caused complete disintegration of tissue culture cell plasma membranes, confirming that the same lipid-based mechanism active against viruses also lyses mammalian cells in vitro.^{[1, 2]} This was a crucial and sobering finding: the fatty acids released during milk storage did not discriminate between viral envelopes and host cell plasma membranes. Both were disrupted by the same mechanism—membrane solubilization. The 1987 authors explicitly called for studies to establish whether human milk lipids achieve antimicrobial concentrations in the infant stomach and intestines without causing cellular damage—a question that remained incompletely answered even after their work.

In a 1994 follow-up paper, Thormar and colleagues reported that stored human milk achieved 3,000-fold to 10,000-fold inactivation of visna virus and other enveloped viruses after 30 minutes of incubation at 37°C.^[3] The 1994 paper by Thormar and colleagues quantified the extraordinary potency of milk-derived lipids across multiple enveloped virus types, not just visna. A 3,000- to 10,000-fold reduction in viral titer in 30 minutes is comparable to the efficacy of many chemical disinfectants, yet this was achieved by naturally occurring fatty acids released through normal enzymatic activity in stored breast milk.

The Mechanism: Death by Membrane Dissolution

These fatty acids don't just poke holes in viruses—they tear them apart entirely.

At low concentrations, antiviral fatty acids caused leakage from viral envelopes; at higher concentrations, they caused complete disintegration of the envelope and viral particles.^{[1, 3]} Thormar et al. described a dose-dependent destruction mechanism. The fatty acids insert into the lipid bilayer of the viral envelope, initially creating defects that allow leakage of internal contents. As concentration increases, the entire lipid membrane is solubilized—effectively dissolving the virus. This mechanism explains why only enveloped viruses are susceptible: non-enveloped viruses, which lack a lipid membrane, were completely unaffected.

None of the fatty acids or monoglycerides tested had any effect on poliovirus, confirming the lipid envelope is the essential target.^[1] This was the critical negative control. Poliovirus, a non-enveloped virus with a protein capsid instead of a lipid membrane, was completely resistant to every fatty acid and monoglyceride tested. This definitively proved that the antiviral mechanism depends on disrupting lipid bilayers, not on some nonspecific chemical toxicity. The eFeedLink institutional review notes the inactivity against non-enveloped viruses is consistent across the literature.

Scale & Potency: Monoglycerides vs. Free Fatty Acids

Monolaurin is up to 10 times more potent than the fatty acid it comes from.

Monoglycerides of medium-chain fatty acids were antiviral at concentrations up to 10 times lower than the corresponding free fatty acids.^{[1, 3]} This was one of the most striking quantitative findings from Thormar's 1987 paper. For example, if lauric acid required a certain concentration to inactivate herpes simplex virus, monolaurin (its monoglyceride) achieved the same inactivation at one-tenth the concentration. The 1994 follow-up confirmed that 1-monoglycerides and ethers of medium-chain fatty acids are more antiviral than their corresponding free fatty acids across multiple enveloped virus types.

The fatty acid concentration required for maximum viral inactivation varied by as much as 20-fold across different active fatty acid species.^[1] Not all active fatty acids are created equal. Even within the active group, there was a 20-fold range in the concentration needed for peak activity. This variability likely reflects differences in chain length, saturation, and how each fatty acid partitions into different types of lipid bilayers. It also means that in complex biological mixtures like milk, the combined effect of multiple fatty acids may be synergistic.

Modern Applications: From Lab Bench to Farms and Clinics

A finding from 1987 breast milk research is now protecting livestock worldwide.

A 1994 paper by Isaacs, Kim, and Thormar demonstrated that adding medium-chain antiviral lipids to human blood products containing HIV-1 and HIV-2 reduced cell-free virus concentration by up to 11 log10 TCID50/ml—a 100-billion-fold reduction.^[4] Isaacs, Kim, and Thormar demonstrated that the same lipids found in breast milk could dramatically reduce HIV titers in blood products. An 11-log10 reduction means eliminating all but one in 100 billion viral particles (10^11-fold). Critically, the same paper noted that these lipids also disrupt cell membranes and can lyse leukocytes that carry virus intracellularly—meaning they may act on both cell-free and cell-associated virus populations. The treatment did not interfere with most clinical laboratory assays.

Glycerol monolaurate (GML) inhibits wild-type African Swine Fever Virus infection in porcine macrophages in vitro, offering a potential biosecurity tool against a disease with no approved commercial vaccine.^{[5, 6]} African Swine Fever has caused substantial economic losses in pig-producing regions worldwide. With no vaccine available, the in-vitro finding that GML can inhibit wild-type ASFV infection in porcine macrophages—the virus's natural target cells—represents an important lead. The Frontiers in Animal Science 2022 review documents that MCMGs are being adopted as feed additives for swine and poultry, though GML's specific commercial adoption for ASFV is still at the research and biosecurity-tool stage rather than widespread deployment.

A 2023 Frontiers in Veterinary Science study found that monolaurin reduced viral load and minimized organ damage in piglets infected with Seneca Valley virus in vivo.^[7] This is one of the few controlled in-vivo animal studies of monolaurin's antiviral effects. Su et al. demonstrated that monolaurin treatment in SVV-infected piglets improved survival rates and reduced pathological symptoms. The proposed mechanism involved modulation of cytokine release and enhancement of interferon-gamma production, suggesting that monolaurin's in-vivo activity may include immune-modulatory effects beyond direct membrane disruption.

Medium-chain monoglycerides are classified as Generally Recognized As Safe (GRAS) by the US FDA (GRN 174, 2005).^[5] Unlike novel pharmaceutical antivirals that require years of safety testing, monoglycerides like GML already have extensive safety profiles from decades of use as food emulsifiers, preservatives, and lubricants. This regulatory advantage lowers the barrier to adoption in feed and food safety applications. The Frontiers in Animal Science 2022 review notes that the industry is shifting toward MCMGs partly because of regulatory restrictions on antibiotics, including the US Veterinary Feed Directive.

Resistance and Evolutionary Constraints

Viruses can outsmart drugs—but they face a fundamental barrier against outsmarting their own membrane.

Diacylglycerols and triacylglycerols (the intact fat molecules in foods) are completely inactive against viruses—only free fatty acids and monoglycerides are antiviral.^{[1, 2]} This is why eating coconut oil does not directly deliver antiviral benefits. The triglycerides in coconut oil must first be hydrolyzed by lipase enzymes into free fatty acids and monoglycerides before any antiviral activity manifests. This is precisely what happens in breast milk during storage (milk lipases do the hydrolysis) and potentially in the infant gut (pancreatic and gastric lipases). Thormar 1987 established this distinction, and it is independently confirmed in the eFeedLink institutional review.

Caveats and open questions

What this paper doesn't settle

The fundamental question raised in the 1987 paper—whether antiviral lipid concentrations are actually achieved in the infant gastrointestinal tract—remains incompletely answered. Additionally, the primary paper noted that antiviral fatty acids also lyse mammalian cells, raising dose-toxicity concerns for any therapeutic application. The precise molecular mechanism by which GML blocks HIV-1 entry after CD4 engagement but before coreceptor binding is not fully characterized; the source literature confirms the step but not the detailed molecular interaction. The resistance-prevention argument is theoretically sound and endorsed in peer-reviewed reviews, but has not been rigorously tested in viral passage experiments. The exact carbon-number boundaries of the active versus inactive fatty acid chain lengths are implied by the data rather than explicitly enumerated in the primary paper.

The honest skeptical read

The primary paper and most subsequent mechanistic work are in vitro studies. Skeptics rightly note that dissolving viral membranes in a test tube is vastly different from doing so in a living organism, where concentrations are diluted, fatty acids are rapidly metabolized, and the same membrane-disrupting activity could harm host tissues. The 2025 COVID-19 cohort study is observational and cannot establish causation—higher monolaurin levels may simply be a marker of better overall health, higher coconut oil intake, or other dietary factors rather than a direct protective effect. Thormar himself called for in-vivo studies to establish infant gut efficacy in 1987; that call has still not been fully answered.

Common misconception

A widespread misconception is that eating coconut oil directly provides antiviral benefits because it is rich in lauric acid. In reality, coconut oil contains lauric acid as part of triglycerides, which are completely inactive against viruses. Enzymatic hydrolysis by lipases is required to release active free fatty acids and monoglycerides. Whether dietary coconut oil achieves sufficient local concentrations of active monolaurin in relevant tissues after digestion and absorption is unproven. Another misconception is that these lipids work against all viruses; they are exclusively active against enveloped viruses and have zero effect on non-enveloped pathogens like norovirus or poliovirus.